Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy

Single-Dose Infliximab in Hepatitis C Genotype 1 Treatmentnaive Patients with High Serum Levels of Tumour Necrosis Factor-Alpha Does Not Influence the Efficacy of Pegylated Interferon Alpha-2B/Ribavirin Therapy

BACKGROUND: Serum tumour necrosis factor-alpha (TNF-α) levels correlate negatively with hepatitis C virus (HCV) antiviral response.

Bibliographic Details
Main Authors: Curtis Cooper, Stephen Shafran, Susan Greenbloom, Robert Enns, John Farley, Nir Hilzenrat, Kurt Williams, Magdy Elkashab, Nabil Abadir, Manuela Neuman
Format: Article
Language:English
Published: Hindawi Limited 2014-01-01
Series:Canadian Journal of Gastroenterology and Hepatology
Online Access:http://dx.doi.org/10.1155/2014/367131

Internet

http://dx.doi.org/10.1155/2014/367131

Similar Items